Laigo Bio seals €11.5M seed led by Kurma Partners and Curie BV

Laigo Bio, a Dutch biotech company pioneering targeted protein degradation, has secured an €11.5M seed round to advance its SureTAC™ platform for oncology and autoimmune diseases. The financing was co-led by Kurma Partners and Curie Capital BV, with participation from Angelini Ventures. This round also reaffirms the strategic collaboration with Argobio Studio, the Paris-based venture studio whose spinout model the company continues to back and leverage in Europe’s early‑stage ecosystem. Lola Buono, Senior Associate at Angelini Ventures, will serve as an observer on Laigo Bio’s board as part of the hands-on support given to the company’s growth trajectory.

The investment landscape for breakthrough modalities like targeted protein degradation is expanding across Europe, driven by a demand for therapies that can tackle previously undruggable targets with improved safety profiles. Laigo Bio’s seed round exemplifies how specialized capital, paired with cross-border collaboration, accelerates the translation of novel biology into preclinical programs poised for faster progress toward clinical testing and patient impact.

SureTAC™ stands at the core of Laigo Bio’s approach, enabling selective removal of disease-causing proteins from cell surfaces. By focusing on precision degradation, the platform aims to reduce off-target effects and unlock therapeutic opportunities across multiple cancer subtypes and autoimmune conditions. The seed funding provides essential support for expanding preclinical activities, validating target panels, and preparing for partnering discussions with large‑molecule and small‑mauge platforms alike.

Lola Buono will lead investor engagement as an observer on the board, underscoring the close collaboration between Laigo Bio’s scientific leadership and its premier funding syndicate. Dr. Matthew Baker, who leads Laigo Bio’s scientific team, will continue to drive the company’s strategy and execution while working to translate the platform’s potential into meaningful clinical candidates.

For the broader European biotech community, the Laigo Bio round highlights a growing pattern: venture studios and specialist funds joining forces with corporate-backed venture arms to seed ambitious platforms at the earliest stages. The involvement of Angelini Ventures alongside cross-border backers not only validates Laigo Bio’s technology but also signals a maturation of the ecosystem where European spinouts can attract multi-path investor support and move swiftly from discovery to development.

Looking ahead, Laigo Bio intends to deploy the new capital toward expanded preclinical programs, target validation, and strategic partnerships that can accelerate the path to first-in-human studies. As investor interest in targeted protein degradation strengthens, the company’s trajectory will be a key indicator of Europe’s capacity to produce platform technologies with durable clinical and patient impact.